# Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

> **NCT00362349** · PHASE3 · COMPLETED · sponsor: **CSL Limited** · enrollment: 19 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura (ITP)

## Interventions

- **DRUG:** IgNextGen 10%

## Key facts

- **NCT ID:** NCT00362349
- **Lead sponsor:** CSL Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362349, "Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00362349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*